表紙
市場調査レポート

発熱性好中球減少症:パイプライン製品の分析

Febrile Neutropenia - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 251568
出版日 ページ情報 英文 61 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
発熱性好中球減少症:パイプライン製品の分析 Febrile Neutropenia - Pipeline Review, H1 2016
出版日: 2016年04月27日 ページ情報: 英文 61 Pages
概要

発熱性好中球減少症は、発熱を伴い、しばしば他の感染症のような兆候があり、血液中の好中球の顆粒細胞(一種の白血球)の異常に低い好中球減少の患者の中に見られます。発熱性好中球減少症は、好中球の減少という形で進展しますが、骨髄抑制療法において、化学療法に伴う合併症として一般的に捉えられています。

当レポートでは、発熱性好中球減少症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

発熱性好中球減少症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

発熱性好中球減少症:企業で開発中の治療薬

発熱性好中球減少症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

発熱性好中球減少症:企業で開発中の製品

発熱性好中球減少症の治療薬開発に従事している企業

  • Apotex Inc.
  • Biogenomics Limited
  • Coherus BioSciences, Inc.
  • Dr. Reddy's Laboratories Limited
  • Richter Gedeon Nyrt.
  • Sandoz International GmbH
  • Therapeutic Proteins International, LLC
  • USV Limited

発熱性好中球減少症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

発熱性好中球減少症:最近のパイプライン動向

発熱性好中球減少症:休止中のプロジェクト

発熱性好中球減少症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7885IDB

Summary

Global Markets Direct's, 'Febrile Neutropenia - Pipeline Review, H1 2016', provides an overview of the Febrile Neutropenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Febrile Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Febrile Neutropenia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Febrile Neutropenia
  • The report reviews pipeline therapeutics for Febrile Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Febrile Neutropenia therapeutics and enlists all their major and minor projects
  • The report assesses Febrile Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Febrile Neutropenia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Febrile Neutropenia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Febrile Neutropenia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Febrile Neutropenia Overview
  • Therapeutics Development
    • Pipeline Products for Febrile Neutropenia - Overview
    • Pipeline Products for Febrile Neutropenia - Comparative Analysis
  • Febrile Neutropenia - Therapeutics under Development by Companies
  • Febrile Neutropenia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Febrile Neutropenia - Products under Development by Companies
  • Febrile Neutropenia - Companies Involved in Therapeutics Development
    • Apotex Inc.
    • Biogenomics Limited
    • Coherus BioSciences, Inc.
    • Dr. Reddy's Laboratories Limited
    • Richter Gedeon Nyrt.
    • Sandoz International GmbH
    • Therapeutic Proteins International, LLC
    • USV Limited
  • Febrile Neutropenia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • EC-18 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • plinabulin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Febrile Neutropenia - Recent Pipeline Updates
  • Febrile Neutropenia - Dormant Projects
  • Febrile Neutropenia - Product Development Milestones
    • Featured News & Press Releases
      • Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
      • Feb 01, 2016: Coherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study
      • Dec 21, 2015: Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma for Commercial Supply of CHS-1701
      • Dec 08, 2015: Coherus BioSciences Reports Update to CHS-1701 Program
      • Dec 08, 2015: EMA started the evaluation of Richter's marketing authorisation application for biosimilar pegfilgrastim
      • Nov 18, 2015: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA
      • Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study
      • May 30, 2012: Aequus Presents Proof Of Concept Data Of GlycoPolymer Technology At International Symposium For Polymer Therapeutics
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Febrile Neutropenia, H1 2016
  • Number of Products under Development for Febrile Neutropenia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Febrile Neutropenia - Pipeline by Apotex Inc., H1 2016
  • Febrile Neutropenia - Pipeline by Biogenomics Limited, H1 2016
  • Febrile Neutropenia - Pipeline by Coherus BioSciences, Inc., H1 2016
  • Febrile Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016
  • Febrile Neutropenia - Pipeline by Richter Gedeon Nyrt., H1 2016
  • Febrile Neutropenia - Pipeline by Sandoz International GmbH, H1 2016
  • Febrile Neutropenia - Pipeline by Therapeutic Proteins International, LLC, H1 2016
  • Febrile Neutropenia - Pipeline by USV Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Febrile Neutropenia Therapeutics - Recent Pipeline Updates, H1 2016
  • Febrile Neutropenia - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Febrile Neutropenia, H1 2016
  • Number of Products under Development for Febrile Neutropenia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top